- NeuroScientific Biopharmaceuticals is teaming up with the Institute of Respiratory Health and the University of Western Australia to find a treatment for post-COVID fibrosis
- Then the disease can cause lasting damage to the lungs, even in young adults, and could potentially become one of the largest future burdens on global healthcare
- However, recent data has shown that a protein known as Metallothionein can protect the lungs from injury and fibrosis
- This is where NSB comes in: its flagship candidate, EmtinB, designed to mimic the protein in patients
- NSB and UWA’s will now research the protein and its viability as a post-COVID fibrosis treatment, with data set for release in the first half of 2021
- On the market this afternoon, NSB remains steady and is trading for 34 cents per share
